Eisai to Acquire Morphotek to Expand into Biologic Therapeutics

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 4
Volume 16
Issue 4

Eisai to Acquire Morphotek to Expand into Biologic Therapeutics

TOKYO, Japan—Eisai Co. Ltd and Eisai Corporation of North American (Woodcliff Lake, New Jersey) have signed a definitive agreement to acquire Morphotek (Exton, Pennsylvania) for $325 million. The acquisition is pending subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Morphotek develops therapeutic monoclonal antibodies and is evaluating two in early-stage clinical trials. Eisai's portfolio of oncology drugs currently includes small-molecule anticancer agents.

Articles in this issue
Curcumin Evaluated for the Treatment of Pancreatic Cancer
Tykerb Approved for Metastatic HER2+ Breast Cancer
'Male Lumpectomy' Via Focal Cryoablation Expands Treatment Options for Selected Prostate Cancer Patients
Drug for BPH May Also Reduce the Risk of Prostate Cancer
Phase III Trial of Prostvac-VF Is Launched
Electronic System Reminds Patients to Schedule Exams
Phase II Trial of Panzem for Renal Cell Carcinoma Initiated
Chemotherapy May Enrich Tumorigenic Cells in Breast Ca
Hand-Assisted Laparoscopic Technique May Reduce Surgery Time in Colon Cancer: New Study Is Underway
Watchful Waiting Management for Prostate Ca a Hard Sell
Once-Weekly SC Idraparinux Equals Standard DVT Rx
Patients Using Unapproved Cancer Agent
CT Lung Screens: No Lives Saved
Transgene Enrolls First Patients in Trial of TG 1042 in CBCL
FDA Updates Warning Labels of ESAs in Cancer Patients
Recent Videos
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Related Content
From phase 3 trial updates to results on trispecific antibodies, ASH 2025 may feature a variety of practice-shifting presentations across multiple myeloma.

ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?

Russ Conroy
December 4th 2025
Article

From phase 3 trial updates to results on trispecific antibodies, ASH 2025 may feature a variety of practice-shifting presentations across multiple myeloma.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers

Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers

Andrea I. Nañez, MD;Maria C. Velez, MD;Mae Zakhour, MD;Edward B. Garon, MD, MS
December 4th 2025
Article

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Laparoscopic Distal Gastrectomy Appears Feasible in T4a Gastric Cancer

Russ Conroy
December 3rd 2025
Article

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.

Delving Into the Current State of Clinical Practice in SCLC

Roman Fabbricatore
December 3rd 2025
Article

In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.